Announced Q1 2027 consolidated results and earnings guidance. Net sales of 91,624 million yen, operating income of 13,663 million yen, a marked YoY profit increase. Mentions contributions by segments and outlook revisions.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4527","jir_company_name":"Rohto Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4527-20260806-03.pdf","jir_short_summary":"Announced Q1 2027 consolidated results and earnings guidance. Net sales of 91,624 million yen, operating income of 13,663 million yen, a marked YoY profit increase. Mentions contributions by segments and outlook revisions.","jir_summary":"### Section heading\nIn the Q1 2027 period, the consolidated results show sales exceeding the previous year and a substantial rise in operating income. Contributions by region and by product are illustrated with charts, and revisions to the outlook are discussed.\n\n### Second section heading\nFrom the perspective of shareholder returns and financial stability, the improved performance this period could enhance cash generation and serve as a foundation for long-term capital policy. The performance of core brands and contributions from overseas markets are emphasized as growth drivers going forward.","jir_financial_highlights":"Net sales: 91,624 (YoY +11.8%)\nOperating income: 13,663 (YoY +14.9%)\nEBITDA: 18,159 (YoY +?%)","jir_category":"","jir_hashtags":"#RohtoPharmaceutical, #CompanyFinancials, #ConsolidatedResults, #Q1Results, #MidTermPlan","jir_key_figures":"Net sales: 91,624 million yen\nOperating income: 13,663 million yen\nEBITDA: 18,159 million yen","jir_meta_title":"Rohto Pharmaceutical Q1 Consolidated Financial Highlights | FY2027","jir_meta_description":"Summary of Rohto Pharmaceutical's Q1 FY2027 results. Highlights include net sales, operating income, YoY comparison, segment contributions, and outlook.","jir_og_title":"Rohto Pharmaceutical Q1 Consolidated Financial Highlights","jir_og_description":"Highlights of Rohto Pharmaceutical's Q1 FY2027 results, including net sales, operating income, and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Q1\\\",\\\"FY2026 Q2\\\",\\\"FY2026 Q3\\\",\\\"FY2026 Q4\\\",\\\"FY2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[526,612,681,745,916],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Q1\\\",\\\"FY2026 Q2\\\",\\\"FY2026 Q3\\\",\\\"FY2026 Q4\\\",\\\"FY2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[11000,11500,12500,13000,13663],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"Asia\\\",\\\"Americas\\\",\\\"Europe\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[7250,23845,12800,9800,6200],\\\"backgroundColor\\\":\\\"#4285f4\\\"}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Q1\\\",\\\"FY2026 Q2\\\",\\\"FY2026 Q3\\\",\\\"FY2026 Q4\\\",\\\"FY2027 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Margin\\\",\\\"data\\\":[14.0,14.5,15.0,15.0,15.3],\\\"borderColor\\\":\\\"#3e95cd\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs. Actual\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q1\\\",\\\"FY2026 Q1\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Forecast\\\",\\\"data\\\":[369500,91624],\\\"backgroundColor\\\":\\\"#888\\\",\\\"stack\\\":\\\"A\\\"},{\\\"label\\\":\\\"Actual\\\",\\\"data\\\":[369500,91624],\\\"backgroundColor\\\":\\\"#4285f4\\\",\\\"stack\\\":\\\"A\\\"}]},\\\"options\\\":{\\\"responsive\\\":true}}\"}]","ir_related_company":7770,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97477","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n